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Background: The best method for expressing lung function impairment is undecided. We 
tested in a population of patients with chronic obstructive pulmonary disease (COPD) whether 
forced expiratory volume in 1 second (FEV1) or FEV1 divided by height squared (FEV1/ht2) 
was better than FEV1 percent predicted (FEV1PP) for predicting survival.
Method: FEV1, FEV1PP, and FEV1/ht2 recorded post bronchodilator were compared as 
predictors of survival in 1095 COPD patients followed for 15 years. A staging system for severity 
of COPD was deﬁ  ned from FEV1/ht2 and compared with the Global Initiative for Obstructive 
Lung Disease (GOLD) staging system.
Result: FEV1/ht2 was a better univariate predictor of survival in COPD than FEV1 and both were 
better than FEV1PP. The best multivariate model for predicting survival included FEV1/ht2, age 
and sex. Comparing the GOLD stages with the FEV1/ht2 groups found that survival was more 
coherent within each FEV1/ht2 group than it was within each GOLD stage. FEV1/ht2 had 60% 
more people in its most severe group than the severest GOLD stage with these extra subjects 
having equivalently poor survival and had 155% more in the least severe group with equivalent 
survival. GOLD staging misclassiﬁ  ed 51% of subjects with regard to survival.
Conclusion: We conclude that GOLD criteria using FEV1PP do not optimally stage COPD 
with regard to survival. An alternative strategy using FEV1/ht2 improves the staging of this 
disease. Studies which stratify COPD patients to determine the effect of interventions such as 
drug trials, rehabilitation, or management guidelines should consider alternatives to the GOLD 
classiﬁ  cation.
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Introduction
Lung function measurements are made to help determine if a subject has an 
abnormality of lung function and also to monitor a disease or its response to treatment. 
The degree of any abnormality may be needed to determine choices about therapy 
or level of disability beneﬁ  t but may also be needed to estimate prognosis. To 
determine if a lung function result is abnormal the American Thoracic Society (ATS) 
and European Respiratory Society (ERS) recommend (Quanjer et al 1993; ATS 1994) 
that the individual’s lung function data should be compared with a predicted value 
using the method of standardized residuals (SR). SR are calculated from:
(Recorded FEV1 – Predicted FEV1)/RSD
where RSD is the residual standard deviation from the regression equation used for 
the prediction, so that an FEV1SR of –1.645 is at the lower 90% conﬁ  dence limit of 
normality.
When it comes to expressing the degree of any such abnormality, that is the 
severity of impairment, there is no agreed method that gives equivalent results for 
all ages and both sexes. The method of percent of predicted (PP) is widely used for 
expressing disease severity (ATS 1987) but its validity is not based on statistical 
evidence (Sobol and Weinheimer 1966; Miller and Pincock 1988). SR are potentially International Journal of COPD 2007:2(4) 658
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ﬂ  awed for expressing severity in that a young subject’s 
predicted value is much higher than that for an older subject, 
so a young subject can have a forced expiratory volume in 
1 second (FEV1) 5 SR below predicted which for an older 
subject would never be found as the FEV1 would have to be 
below zero.
The PP method has been used in many epidemiological 
studies (Lange et al 1990; Knuiman et al 1999; Schunemann 
et al 2000; Thomason and Strachan 2000) showing that FEV1 
expressed as percent predicted (FEV1PP) is an important 
predictor of survival. However, in chronic obstructive 
pulmonary disease (COPD) it was raw FEV1 that was 
originally shown to relate to survival (Burrows and Earle 
1969). The Framingham study found that FEV1 divided by 
height squared was an important predictor of survival (Ashley 
et al 1975) in the general population, a ﬁ  nding recently 
reinforced from the Reykjavik study (Chinn et al 2007). 
More recently the PP method has been used with arbitrary 
threshold values in guidelines with regard to specifying 
the severity of COPD (ATS 1995; Siafakas et al 1995) and 
asthma (British guideline 2005) and the Global Initiative for 
Chronic Obstructive Lung disease (GOLD) has empirically 
deﬁ  ned 5 stages of severity (NIH et al 2005) based on 
FEV1PP. Concern has been raised that this system is not 
evidence-based (Kerstjens 2004).
Prediction equations such as those recommended by the 
ERS (Quanjer et al 1993) are used to derive a predicted value 
for an individual which tries to take into account the effect 
of age, height, and sex on lung function, but this is imprecise 
with wide conﬁ  dence intervals and the data from which the 
equations are derived may not perfectly match the patient 
under consideration. Therefore any method of relating lung 
function to a predicted value may introduce some age, height 
or sex related error. We have therefore tested whether lung 
function impairment expressed as absolute FEV1 or standard-
ized by height might be better than FEV1PP and FEV1SR in 
predicting survival in COPD.
Methods
We have reanalyzed the data from 1095 subjects with COPD 
who had been recruited from 1983 to 1988 in a respiratory 
clinic in Copenhagen into a longitudinal study to look at 
predictors of their all cause mortality (Hansen et al 1999, 
2001) over a 15 year follow up. They were all assessed by 
a consultant respiratory physician and diagnosed as having 
COPD based from symptoms of cough, sputum, lack of 
variability in airﬂ  ow limitation, lack of allergy and atopy, 
their smoking history and their FEV1 as a percent of forced 
vital capacity (FVC) had to be less than 89% of their predicted 
value, in accordance with ERS recommendations at that time 
(Siafakas et al 1995). There was no within day variation 
in lung function and no signiﬁ  cant acute or corticosteroid 
reversibility to their airﬂ  ow obstruction. We have analyzed 
the spirometric data on entry into the study which were 
obtained after both an inhaled bronchodilator and a 2 week 
trial of oral corticosteroids, ie, maximally bronchodilated as 
per GOLD recommendation (NIH et al 2005).
Each subject’s data had their FEV1 expressed as percent 
predicted (PP) using ERS prediction equations (Quanjer et al 
1993), as FEV1 divided by height squared (FEV1/ht2) and 
as standardized residuals (SR) (Miller et al 1985; Quanjer 
et al 1993). Subjects were staged by GOLD criteria (NIH 
et al 2005) and also arbitrarily by FEV1/ht2 into 4 stages as 
deﬁ  ned in Table 1. Because GOLD stage 1 only identiﬁ  ed 
6 subjects in this cohort the staging by FEV1/ht2 was into 4 
and not 5 arbitrary groups in order to allow fairer comparison 
between the two classiﬁ  cation systems.
Statistical analysis was undertaken using SPSS for Win-
dows version 11.5 (Microsoft, Redmond, WA). Cox propor-
tional hazards regression analysis was used for predicting all 
cause mortality using quintiles of putative predictor variables. 
This method is a special form of multiple regression that 
allows for the inclusion of the censored data for those cases 
for which the end point of death has not yet occurred. The 
best prediction models were judged on the basis of highest 
global chi-square (χ2) value and greatest reduction in –2 times 
the log likelihood (–2LL) for different models (Cox 1972). 
The proportional hazards model assumes that the ratio of the 
estimated hazard functions for any two observations with 
different values for the independent (predictor) variables is 
constant over time. This assumption was checked for each 
Table 1 Classiﬁ  cation criteria for GOLD and FEV1/ht2
staging from spirometry alone. FEV1% is the FEV1 expressed
as a percentage of FVC. FEV1PP is the FEV1 expressed as a 
percentage of the subject’s predicted value
GOLD staging  FEV1/ht2 staging
Stage Criteria  Stage Criteria
0 FEV1%   70%   
1 FEV1% < 70% and 
 FEV1PP   80%   1  0.5 < FEV1/ht2
2 FEV1% < 70% and
 FEV1 PP < 80% 2 0.4  < FEV1/ht2   0.5
3 FEV1% < 70% and
 FEV1PP < 50% 3  0.3  < FEV1/ht2   0.4
4 FEV1% < 70% and
 FEV1PP < 30% 4  FEV1/ht2   0.3International Journal of COPD 2007:2(4) 659
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model from plots of cumulative hazard against survival time 
stratiﬁ  ed by the relevant FEV1 index. For the multivariate 
Cox models, hazard ratios were calculated by contrasting 
risk against that for the ﬁ  rst stage of each index. Subjects 
were categorized by their GOLD and FEV1/ht2 stages and 
Kaplan-Meier survival analysis was used to estimate mean 
survival for every subgroup of subjects defined by the 
4 × 4 matrix of GOLD and FEV1/ht2 stages. Mean survival 
was used rather than median survival since some subgroups 
were too small for reliable estimates of the median.
Results
Age, height, and spirometric values are shown in Table 2 
for the 1095 subjects of whom 644 (59%) were female. 
The median survival from entry into the longitudinal study 
was 3208 days, with 723 (66%) dying during the period of 
follow up (median survival 2231 days versus 4083 days for 
survivors), of whom 404 were female which was slightly 
lower than the number (425) expected by chance (χ2 = 7.57, 
df = 1, p = 0.006). Univariate Cox proportional hazards 
models for survival were derived with the following variables 
as predictors: height, sex, body mass index (BMI), FEV1, 
FEV1/ht2, FEV1PP and FEV1SR. Table 3 shows the strength 
of univariate association with survival for each index as a 
continuous variable with FEV1/ht2 being the best univariate 
predictor.
To allow hazard ratios for various predictors to be cal-
culated Cox regression models were constructed with sex 
and quintiles of age and the various lung function indices. 
The best multivariate model was with FEV1/ht2, age and 
sex (χ2 = 289, −2LL = 9025) and the hazard ratios for the 
predictors are shown in Table 4. The other FEV1 indices 
gave less good models with the next best being with raw 
FEV1, followed by FEV1PP and then FEV1SR. The model 
with FEV1/ht2 had a lower HR for male sex than that with 
raw FEV1 suggesting the standardization by height had taken 
into account some sex difference. The models with PP and 
SR found the HR for male sex was no longer signiﬁ  cant. 
BMI quintiles improved each of these models slightly but 
only the lightest BMI quintile had a signiﬁ  cantly increased 
hazard ratio (HR = 1.4, 95% CL 1.1 to 1.8) compared with 
the other BMI quintiles.
Figure 1 shows mean survival (with 95% CL bars) for 
each FEV1/ht2 group compared with the GOLD stage. Figure 
2 shows the numbers of subjects in each of the staging groups 
and the full data used in these Figures is presented in Table 5. 
The mean survival for the FEV1/ht2 groups decreases progres-
sively and fairly evenly whereas the survival for GOLD 0 
and 2 are very similar. There were 308 subjects in FEV1/ht2 
stage 1 which was 2.5 times the number of subjects in the 
equivalent GOLD stage 0 (121). More than half of the sub-
jects in each of GOLD stages 2 and 3 were in discordant 
FEV1/ht2 stages and the worst FEV1/ht2 stage included 1.6 
times as many subjects as did GOLD stage 4 (199 versus 
126). Overall 51% of subjects were in discordant staging 
groups. The poor staging by GOLD was conﬁ  rmed from 
a Cox regression model using just the GOLD stage as 
predictor for survival, where the χ2 value was only 81, which 
was signiﬁ  cantly inferior to a model using just the FEV1/ht2 
stage which yielded χ2 value of 166.
Discussion
We present the ﬁ  rst evidence that FEV1PP is not as good as 
either raw FEV1 or FEV1/ht2 at predicting survival in a cohort 
of COPD patients. This ﬁ  nding conﬁ  rms concerns previously 
expressed about the use of PP as a method for expressing 
Table 2 Descriptive data for age, height and spirometric values
for the 1095 patients in the study (644 female) showing mean,
standard deviation (SD) and median values
 Mean  (SD)  Median
Age 61.8  (9.9)  63.0
Ht in meters  1.66 (0.09)  1.65
FVC in L  2.25 (0.76)  2.14
FVCSR  −1.87 (1.10)  −1.86
FEV1 in L  1.21 (0.45)  1.14
FEVSR  −3.21 (1.02)  −3.24
FEV1PP 46.7  (14.5)  45.5
FEV1/ht2   0.43 (0.15)  0.41
FEV1% 54.4  (12.2)  55.0
FEV1%SR  −3.31 (1.76)  −3.23
PEF in L/s  3.60 (1.47)  3.33
PEFSR  −3.11 (1.32)  −3.28
Table 3 Univariate analysis: Indices that were found by Cox 
regression to be univariate predictors of survival with χ2 value 
for strength of prediction and its signiﬁ  cance value
Index  χ2 value  p value
FEV1/ht2   161  <0.0001
Age 159 <0.0001
FEV1 127  <0.0001
FEV1PP 111  <0.0001
FEV1% 97  <0.0001
FEV1SR 18  <0.0001
Sex 12  <0.001
BMI 11  <0.001
Weight 8  0.004
Height 0 International Journal of COPD 2007:2(4) 660
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Table 4 Multivariate analysis: The table shows the covariate hazard ratios (HR) for death (with 95% conﬁ  dence limits) for Cox pro-
portional hazards models using sex and the quintiles of age and various methods for expressing FEV1 impairment. The HR values are 
contrasts against the hazard estimated for the ﬁ  rst stage of each group and for male contrasted with female. Chi-square values are 
shown for each model
   FEV1/ht2   Raw FEV1   FEV1PP   FEV1SR
   Chi  square  = 289   Chi square = 276   Chi square = 269   Chi square = 218 
    HR   95% CL   HR   95% CL   HR   95% CL   HR   95% CL 
Age   youngest quintile   1.0     1.0     1.0     1.0  
  quintile 2   1.8   (1.3 to 2.4)   1.8   (1.3 to 2.4)   2.0   (1.5 to 2.6)   2.1   (1.6 to 2.9) 
  quintile 3   2.2   (1.6 to 2.9)   2.2   (1.7 to 3.0)   2.6   (2.0 to 3.5)   3.1   (2.4 to 4.2) 
  quintile 4   2.5   (1.8 to 3.3)   2.5   (1.9 to 3.3)   3.2   (2.4 to 4.3)   4.1   (3.1 to 5.4) 
  oldest quintile   3.1   (2.4 to 4.1)   3.1   (2.3 to 4.1)   4.3   (3.3 to 5.7)   6.0   (4.5 to 7.9) 
FEV1 index  best quintile   1.0     1.0     1.0     1.0  
  quintile 2   1.6   (1.2 to 2.1)   1.6   (1.2 to 2.1)   1.5   (1.1 to 1.9)   1.2   (0.9 to 1.5) 
  quintile 3   2.0   (1.5 to 2.7)   1.9   (1.4 to 2.5)   1.8   (1.4 to 2.4)   1.6   (1.3 to 2.0) 
  quintile 4   2.4   (1.8 to 3.2)   2.4   (1.8 to 3.2)   2.4   (1.8 to 3.0)   2.0   (1.5 to 2.5) 
  worst quintile   4.0   (3.0 to 5.2)   3.9   (3.0 to 5.1)   3.4   (2.6 to 4.3)   2.6   (2.0 to 3.3) 
Male     1.5   (1.3 to 1.7)   1.8   (1.5 to 2.0)   1.1   (0.9 to 1.3)   1.1   (0.9 to 1.3) 
Figure 1 The mean survival for each FEV1/ht2 group and each GOLD stage with 95% conﬁ  dence limit bars and the number of subjects in each column.
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impairment in FEV1 (Sobol and Weinheimer 1966; Miller 
and Pincock 1988). The assumption that a ﬁ  xed level of 
FEV1PP means the same level of impairment for different 
subjects is clearly ﬂ  awed since, for example, young adults 
with cystic ﬁ  brosis can survive with an FEV1 just as low in 
absolute terms as old subjects, with their PP values going 
as low as 10% (Sood et al 2001) which is much lower than 
that seen in the elderly.
Several studies have shown that survival in COPD 
relates to FEV1 (Burrows and Earle 1969; Gorecka et al 
1997; Thomason and Strachan 2000) with values lower than 
0.75 litre having a 3 year survival of only 50% (Burrows and 
Earle 1969). When using the GOLD criteria to stratify our 
subjects there were only 11.5% subjects in stage 4 whereas 
the method based on FEV1/ht2 increased the proportion in 
the severest stage to 18.2% and yet these had a comparably 
poor survival. This suggests that estimating severity of 
COPD from FEV1PP criteria does not identify all those 
subjects who are most severely affected. Concern has been 
expressed that the GOLD criteria, which were arbitrarily 
chosen to deﬁ  ne severity of COPD, are not based on any 
evidence of their ability to predict survival or any other aspect 
of COPD management (Kerstjens 2004). Our data provide 
strong evidence that the GOLD criteria are not adequate 
for correctly placing individual patients into disease stage 
categories that relate to survival. We do not have data on 
individual symptoms to determine how the two classiﬁ  cation 
systems of COPD relate to symptoms and performance but 
this could be veriﬁ  ed in other data sets.
Furthermore we found that within the GOLD stages 
there were subgroups with differing survival that were 
better stratiﬁ  ed by FEV1/ht2 staging. The deﬁ  nition of stage 
4 by GOLD criteria severity (NIH et al 2005) can include 
subjects with less severe spirometry results but who are in 
type 2 respiratory failure. Therefore it is possible that some of 
our subjects allocated to GOLD 3 might in fact be in GOLD 
stage 4 if their arterial gas results were known. However, it 
seems unlikely that the 85 subjects in the worst FEV1/ht2 
stage but who we classiﬁ  ed as GOLD 3 had been in type 
2 respiratory failure on entry into the study because their 
Figure 2 Plot of the number of subjects in each of the groups for the FEV1/ht2 staging system on the left and the GOLD staging system on the right with the mean survival 
of each group stated inside the relevant column.
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mean survival was 6.1 years. It seems clear that FEV1/ht2 
can stratify subjects with COPD into survival groups better 
than GOLD criteria without recourse to other data such as 
arterial gases.
Recent work has emphasized that multivariate analysis 
including data on BMI, the degree of airﬂ  ow obstruction as 
FEV1PP, dyspnoea, and exercise capacity measured by the 
six-minute-walk test (BODE index) was better at predicting 
survival in COPD than univariate analysis (Celli et al 2004). 
However, our data suggest that the use of FEV1/ht2 instead 
of FEV1PP as the index of airﬂ  ow obstruction in this form 
of multivariate analysis would further improve the survival 
prediction.
Additional problems with the PP and SR methods for 
expressing degree of abnormality occur because they require 
an estimate of a subject’s predicted value. The regression 
equations recommended by the ERS for FEV1 only account 
for about 58% of the variation of FEV1 in normal subjects, 
thus the predicted value is not a precise estimate and will 
include errors related to sex, age, height, and technical 
issues (Quanjer et al 1993). Furthermore if the subject 
whose predicted value is being derived is from a population 
different from that used to derive the prediction equation or 
the subject’s age is outside the limits of the population used 
in the equation then further errors will be incurred.
Our data show FEV1/ht2 is better than both raw FEV1 and 
FEV1PP for expressing degree of lung function impairment. 
If this dataset is analyzed with the two sexes considered 
independently then FEV1/ht2 gives results indistinguishable 
from that for raw FEV1 in terms of ability to predict all cause 
mortality. However, in clinical practice it is advantageous to 
have a method for assessing risk that is applicable for both 
sexes in an equivalent way. FEV1/ht2 is one way of taking 
some of the sex differences in lung function into account 
without introducing the potential errors inherent in 
trying to predict what a given subject’s FEV1 should be 
(Quanjer et al 1993). A recent study of all cause mortality 
in a general population conﬁ  rmed that FEV1/ht2 was better 
related to survival than FEV1PP (Chinn et al 2007) and we 
now conﬁ  rm this ﬁ  nding in a cohort of COPD patients.
We conclude that FEV1/ht2 is better related to survival 
in COPD than FEV1PP and so may be the best method for 
expressing degree of FEV1 impairment. Our ﬁ  ndings indicate 
that applying the GOLD criteria to COPD management does 
not optimally classify those most severely affected. So studies 
which need to stratify COPD patients in order to determine 
the potential beneﬁ  ts of interventions such as drug trials, 
rehabilitation programmes or even discharge policies should 
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not just consider the GOLD classiﬁ  cation but also consider 
using FEV1/ht2 or other strategies to assess disease severity 
correctly. Our evidence suggests using GOLD criteria alone 
will have suboptimal power to show any beneﬁ  ts from such 
interventions. We believe future scientiﬁ  c endeavor in COPD 
must not be limited by the arbitrary GOLD staging which 
here failed to identify over one third of the worst prognosis 
group. Alternative classiﬁ  cations should now be prospec-
tively compared so that the best results for managing and 
researching into COPD can be achieved.
References
[ATS] American Thoracic Society. 1987. Standardization of spirometry: 
1987 update. Am Rev Respir Dis, 136:1286–96.
[ATS] American Thoracic Society. 1995. Standardization of spirometry. 
1994 update. Am J Respir Crit Care Med, 152:1107–36.
[ATS] American Thoracic Society. 1995. COPD Guidelines. Am J Respir 
Crit Care Med, 152:S77–S120.
Ashley F, Kannel WB, Sorlie PD, et al. 1975. Pulmonary function: relation 
to aging, cigarette habit, and mortality. The Framingham Study. Ann 
Intern Med, 82:739–45.
British Guideline. 2003. British guideline on the management of asthma. 
Thorax, 58:Suppl 1.
Burrows B, Earle RH. 1969. Course and prognosis of chronic obstructive 
lung disease. A prospective study of 200 patients. N Engl J Med, 
280:397–404.
Burrows B, Earle RH. 1969. Prediction of survival in patients with chronic 
airway obstruction. Am Rev Respir Dis, 99:865–71.
Celli BR, Cote CG, Marin JM, et al. 2004. The body-mass index, airﬂ  ow 
obstruction, dyspnea, and exercise capacity index in chronic obstructive 
pulmonary disease. N Engl J Med, 350:1005–12.
Chinn S, Gislason C, Aspelund T, et al. 2007. Optimum expression of adult 
lung function based on all-cause mortality: results from the Reykjavik 
study. Respir Med, 101:601–9.
Cox DR. 1972. Regression models and life tables. J Royal Stat Soc, 
B34:187–220.
Gorecka D, Gorzelak K, Sliwinski P, et al. 1997. Effect of long term oxygen 
therapy on survival in patients with chronic obstructive pulmonary 
disease with moderate hypoxaemia. Thorax, 52:667–8.
Hansen EF, Phanareth K, Laursen LC, et al. 1999. Reversible and 
irreversible airﬂ  ow obstruction as predictor of overall mortality in 
asthma and chronic obstructive pulmonary disease. Am J Respir 
Crit Care Med, 159:1267–71.
Hansen EF, Vestbo J, Phanareth K, et al. 2001. Peak ﬂ  ow as predictor of 
overall mortality in asthma and chronic obstructive pulmonary disease. 
Am J Respir Crit Care Med, 163:690–3.
Kerstjens HAM. 2004. The GOLD classification has not advanced 
understanding of COPD. Am J Respir Crit Care Med, 170:212–13.
Knuiman MW, James AL, Divitini ML, et al. 1999. Lung function, 
respiratory symptoms, and mortality: results from the Busselton Health 
Study. Ann Epidemiol, 9:297–306.
Lange P, Nyboe J, Appleyard M, et al. 1990. Spirometric ﬁ  ndings and 
mortality in never-smokers. J Clin Epidemiol, 43:867–73.
Miller MR, Pincock AC, Grove DM. 1985. Patterns of spirogram abnormal-
ity in individual smokers. Am Rev Respir Dis, 132:1034–40.
Miller MR, Pincock AC. 1988. Predicted values: how should we use them? 
Thorax, 43:265–7.
[NIH] National Institutes of Health, National Heart, Lung and Blood 
Institute. 2005. Global strategy for the diagnosis, management, and 
prevention of chronic obstructive pulmonary disease. NHLBI/WHO 
Workshop Report. Update 2005 [online]. Accessed on May 22, 2007. 
URL: http://www.goldcopd.com
Quanjer PhH, Tammeling GJ, Cotes JE, et al. 1993. Standardized lung func-
tion testing. Lung volumes and forced ventilatory ﬂ  ows. Eur Respir J, 
6, (Suppl 16):5–40.
Schunemann HJ, Dorn J, Grant BJ, et al. 2000. Pulmonary function is a 
long-term predictor of mortality in the general population: 29-year 
follow-up of the Buffalo Health Study. Chest, 118:656–64.
Siafakas NM, Vermeire P, Pride NB, et al. 1995. ERS – Consensus state-
ment. Optimal assessment and management of chronic obstructive 
pulmonary disease (COPD). Eur Respir J, 8:1398–420.
Sobol BJ, Weinheimer A. 1966. Assessment of ventilatory abnormality in 
the asymptomatic subject: an exercise in futility. Thorax, 21:445–9.
Sood N, Paradowski LJ, Yankaskas JR. 2001. Outcomes of intensive care 
unit care in adults with cystic ﬁ  brosis. Am J Respir Crit Care Med, 
163:335–8.
Thomason MJ, Strachan DP. 2000. Which spirometric indices best 
predict subsequent death from chronic obstructive pulmonary disease? 
Thorax, 55:785–8.